Wieying Kuo1,2, Thomas Soffers1, Eleni-Rosalina Andrinopoulou3, Tim Rosenow4, Sarath Ranganathan5,6,7, Lidija Turkovic4, Stephen M Stick4,8,9, Harm A W M Tiddens1,2. 1. Department of Pediatric Pulmonology and Allergology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 2. Department of Radiology, Erasmus MC, Rotterdam, The Netherlands. 3. Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands. 4. Telethon Kids Institute, The University of Western Australia, Perth, Australia. 5. Infection and Immunity Theme, Murdoch Children's Research Institute, Melbourne, Australia. 6. Department of Paediatrics, University of Melbourne, Australia. 7. Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Australia. 8. Princess Margaret Hospital for Children, Perth, Western Australia, Australia. 9. School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia.
Abstract
OBJECTIVE: To evaluate lung disease progression using airway and artery (AA) dimensions on chest CT over 2-year interval in young CF patients longitudinally and compare to disease controls cross-sectionally. METHODS: Retrospective analysis of pressure controlled end-inspiratory CTs, 12 routine baseline (CT1 ) and follow up (CT2 ) from AREST CF cohort; 12 disease controls with normal CT. All visible AA-pairs were measured perpendicular to the airway axis. Inner and outer airway diameters and wall (outer-inner radius) thickness were divided by adjacent arteries to compute Ain A-, Aout A-, and AWT A-ratios, respectively. Differences between CF and control data were assessed using mixed effects models predicting AA-ratios per segmental generation (SG). Power calculations were performed with 80% power and ɑ = 0.05. RESULTS: CF, median age CT1 2 years; CT2 3.9 years, 5 males. Controls, median age 2.9 years, 10 males. Total of 4798 AA-pairs measured. Cross-sectionally: Ain A-ratio showed no difference between controls and CF CT1 or CT2 . Aout A-ratio was significantly higher in CF CT1 (SG 2-4) and CT2 (SG 2-5) compared to controls. AWT A-ratio was increased for CF CT1 (SG 1-5) and CT2 (SG 2-6) compared to controls. CF longitudinally: Ain A-ratio was significantly higher at CT2 compared to CT1 . Increase in Aout A-ratio at CT2 compared to CT1 was visible in SG ≥4. Sample sizes of 21 and 58 would be necessary for 50% and 30% Aout A-ratio reductions, respectively, between CF CT2 and controls. CONCLUSION: AA-ratio differences were present in young CF patients relative to disease controls. Aout A-ratio as an objective parameter for bronchiectasis could reduce sample sizes for clinical trials.
OBJECTIVE: To evaluate lung disease progression using airway and artery (AA) dimensions on chest CT over 2-year interval in young CF patients longitudinally and compare to disease controls cross-sectionally. METHODS: Retrospective analysis of pressure controlled end-inspiratory CTs, 12 routine baseline (CT1 ) and follow up (CT2 ) from AREST CF cohort; 12 disease controls with normal CT. All visible AA-pairs were measured perpendicular to the airway axis. Inner and outer airway diameters and wall (outer-inner radius) thickness were divided by adjacent arteries to compute Ain A-, Aout A-, and AWT A-ratios, respectively. Differences between CF and control data were assessed using mixed effects models predicting AA-ratios per segmental generation (SG). Power calculations were performed with 80% power and ɑ = 0.05. RESULTS: CF, median age CT1 2 years; CT2 3.9 years, 5 males. Controls, median age 2.9 years, 10 males. Total of 4798 AA-pairs measured. Cross-sectionally: Ain A-ratio showed no difference between controls and CF CT1 or CT2 . Aout A-ratio was significantly higher in CF CT1 (SG 2-4) and CT2 (SG 2-5) compared to controls. AWT A-ratio was increased for CF CT1 (SG 1-5) and CT2 (SG 2-6) compared to controls. CF longitudinally: Ain A-ratio was significantly higher at CT2 compared to CT1 . Increase in Aout A-ratio at CT2 compared to CT1 was visible in SG ≥4. Sample sizes of 21 and 58 would be necessary for 50% and 30% Aout A-ratio reductions, respectively, between CF CT2 and controls. CONCLUSION: AA-ratio differences were present in young CF patients relative to disease controls. Aout A-ratio as an objective parameter for bronchiectasis could reduce sample sizes for clinical trials.
Authors: Emily M DeBoer; Julia S Kimbell; Kaci Pickett; Joseph E Hatch; Kathryn Akers; John Brinton; Graham L Hall; Louise King; Fiona Ramanauskas; Tim Rosenow; Stephen M Stick; Harm A Tiddens; Thomas W Ferkol; Sarath C Ranganathan; Stephanie D Davis Journal: Respir Physiol Neurobiol Date: 2021-06-19 Impact factor: 1.931
Authors: Merel C J Oudraad; Wieying Kuo; Tim Rosenow; Eleni-Rosalina Andrinopoulou; Stephen M Stick; Harm A W M Tiddens Journal: Pediatr Pulmonol Date: 2020-03-02
Authors: Harm A W M Tiddens; Eleni-Rosalina Andrinopoulou; Joe McIntosh; J Stuart Elborn; Eitan Kerem; Nynke Bouma; Jochem Bosch; Mariette Kemner-van de Corput Journal: PLoS One Date: 2020-11-03 Impact factor: 3.240
Authors: Eline Lauwers; Annemiek Snoeckx; Kris Ides; Kim Van Hoorenbeeck; Maarten Lanclus; Wilfried De Backer; Jan De Backer; Stijn Verhulst Journal: BMC Pulm Med Date: 2021-08-04 Impact factor: 3.317